Business Context and Reporting Period
This Form 8-K is filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on March 5, 2019, with the report date of March 11, 2019. The filing serves to announce financial results for the fourth quarter and full fiscal year ended December 31, 2018, and to disclose the resignation of the Chief Medical Officer.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing the detailed financial results for the fourth quarter and fiscal year 2018, but the data itself is not included in this document.
Material Changes and Corporate Events
- Executive Departure: Dennis D. Kim, M.D., resigned as Chief Medical Officer effective at a date to be agreed upon. The departure was not due to any disagreement with the Company regarding operations, policies, or practices.
- Program Updates: The Company issued updates regarding its drug candidates ZGN-1061 and ZGN-1258.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, risk factors, or management commentary within the text provided. It directs readers to the attached press release for program updates and financial details. The document explicitly states that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific financial figures for Q4 and FY 2018 in the attached Exhibit 99.1 press release.
- Confirm the effective date of Dr. Dennis D. Kim's resignation and the appointment of a successor.
- Review the detailed program updates for ZGN-1061 and ZGN-1258 in the referenced press release.
- Note the discrepancy between the request metadata (Larimar Therapeutics) and the filing registrant (Zafgen, Inc.).